ABSTRACT
Objective To explore the correlation between CD62p and clopidogrel resistance in patients undergoing percutaneous coronary intervention with coronary heart disease combined with diabetes mellitus.Methods 150 patients ndergoing percutaneous coronary intervention with coronary heart disease combined with diabetes mellitus were enrolled in our hospital from August 2013 to December 2016,of all patients accepted clopidogrel treatment,the platelet aggregation rate were analyzed before and after treatment,which all patients divided into two groups as the range of decreasing platelet aggregation rate whether ≥ 10％,clopidogrel effective group (C2) and clopidogrel resistance group (C 1) were detected CD62p and platelet aggregation maximum (PAGM),the relevance of which range with platelet aggregation rate was analyzed.Results After treatment,the platelet aggregation rate of all patient decreased signifieantly (P ＜ 0.05).Of all patients divided into clopidogrel effective group (C2) and clopidogrel resistance group (C 1) as the range of decreasing platelet aggregation rate,and the CD62p of Group C1 decreased compared with before treatment (P ＜ 0.05),the level of CD62p and PAGM in Group C2 were decreasing compared with pre-treatment,and the range of which was larger than those Group C1 (P ＜ 0.05).The reference of CD62p and PAGM in Group C2 (r =0.424,P =0.001) was better than that Group C1 (r =0.387,P =0.020).Conclusions Clopidogrel for patients undergoing percutaneous coronary intervention with coronary heart disease combined with diabetes mellitus possessed inhibition for platelet activity,and clopidogrel resistance might be associated with platelet activity.